ACUTE TOXICITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH ANTITHROMBOGENIC PROPERTIES
https://doi.org/10.36946/0869-7922-2021-1-52-57
Abstract
The paper presents the results of studying the toxicological profile of a new pharmaceutical substance RU891 with antithrombogenic properties. The minimum toxic dose (TDmin) for RU-891 by peroral administration is 230 mg/kg < TDmin ≤ 460 mg/kg. In experiments on the acute toxicity of the compound RU-891, the nature and severity of its damaging effect on the body of experimental animals were established and the safety of its action was evaluated. When studying the toxic effect of the test sample, the tolerated and toxic doses of RU-891 were determined, and the most sensitive organs and systems of the body were identified.
About the Authors
A. A. Spasov
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health; Volgograd Medical Research Center, Laboratory of Experimental Pharmacology
Russian Federation
Russian Federation
Spasov Aleksandr Alekseyevich
400131, Volgograd
A. F. Kucheryavenko
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Kucheryavenko Aida Fatikhovna
400131, Volgograd
D. V. Maltsev
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health;Volgograd Medical Research Center, Laboratory of Experimental Pharmacology
Russian Federation
Russian Federation
Maltsev Dmitriy Vasil’yevich
400131, Volgograd
М. V. Miroshnikov
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Miroshnikov Mikhail Vladimirovich
400131, Volgograd
V. S. Sirotenko
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Sirotenko Viktor Sergeevich
400131, Volgograd
К. Т. Sultanova
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Sultanova Kira Timurovna
400131, Volgograd
К. A. Gaidukova
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Gaidukova Ksenia Andreevna
400131, Volgograd
М. О. Skripka
Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health
Russian Federation
Russian Federation
Skripka Maria Olegovna
400131, Volgograd
References
1. Anisimova V.A., Spasov A.A., Ostrovskii O.V., Dudchenko G.P., Kosolapov V.A., Kucheryavenko A.F. et al. Synthesis and pharmacological activity of 3-aroyl- and 3-hetaroylimidazo[1,2-a] benzimidazoles. Pharmaceutical Chemistry Journal. - 2002. - Vol. 36.- No. 12.- pp. 637-642.
2. Anisimova V.A., Kucheryavenko A.F., Spasov A.A. et al. Synthesis and biological activity of n-acylmethyl derivatives of 9h-2,3-dihydroimidazo- and 10h-2,3,4,10-tetrahydropyrimido[1,2-a] benzimidazoles and their reduction products. Pharmaceutical Chemistry Journal. - 2006. - Vol. 40. – No. 5.- pp. 261-267.
3. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J. et al. Heart disease and stroke statistics (a report from the American Heart Association). Circulation. - 2016. – No. 133. - pp. 38–60.
4. Spasov A.A., Nedogoda V.V., Konan K., Kucheryavenko A.F. Мechanism of reduction of platelet sensitivity to medicines in response to low-energy laser radiation of blood. Hematology and Transfusiology. - 2001. - Vol.46. – No. 2. - pp. 36-39 (in Russian).
5. Bugaeva L.I., Kuzubova E.A., Bukatin M.V., Spasov A.A. Neurotoxicological properties of the drug «Bendazol». Vestnik VolgSMU. - 2012. - No. 2. - pp. 83-86 (in Russian).
6. Golukhova E.Z., Ryabinina M.N. Modern aspects of antiplatelet therapy.Creative Cardiology. - 2013. - No. 1. - pp. 46-58 (in Russian).
7. Kucheryavenko A.F., Anisimova V.A., Gaidukova K.A., Divaeva L.N., Spasov A.A. et al. Antiplatelet activity of a new bicyclic derivative of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a] benzimidazole. Experimental and Clinical Pharmacology. - 2016. - Vol. 79. - No. 5. - pp. 29-32 (in Russian).
8. Kucheryavenko A.F., Spasov A.A., Petrov V.I. et al. Antiplatelet activity of a new benzimidazole derivative. Bulletin of Experimental Biology and Medicine. - 2013. - Vol. 156. - No. 12. - pp. 760- 762 (in Russian).
9. Miroshnikov M.V. et al. The anxiolytic potential of a new series of diazepinobenzimidazole derivatives. Vestnik VolgSMU. - 2018. - Vol. 67. - No. 3. - p. 19 (in Russian).
10. Spasov A.A., Kucheryavenko A.F., Kosolapov V.A., Anisimova V.A. Antithrombogenic activity of antioxidant compounds. Bulletin of Experimental Biology and Medicine. - 2013. - Vol. 155. - No. 6-pp. 740-742 (in Russian).
11. Spasov A.A., Dudchenko G.P., Gavrilova E.S., Kucheryavenko A.F. et al. Diabenol - new antidiabetic substance with geobiological properties. Bulletin of the Volgograd Medical Academy. - 1997. - Vol. 52. - No. 3. - pp. 47-51 (in Russian).
12. Spasov A.A., Kucheryavenko A.F., Anisimova V.A. Calcium-dependent mechanism of antiplatelet action of compound RU-891. Experimental and Clinical Pharmacology. - 2014. - Vol. 77. - No. 3. - pp. 16-19 (in Russian).
13. Spasov A.A., Smirnov A.V., Kucheryavenko A.F. Antithrombotic activity of a new benzimidazole derivative on a model of thrombosis in mice. Bulletin of Experimental Biology and Medicine. - 2014. - Vol. 157. - No. 5. - pp. 595-598 (in Russian).
14. Spasov A.A. et al. Antithrombotic activity of the compound RU-891. Experimental and Clinical Pharmacology. - 2013. - Vol. 76. - No. 6. - pp. 25-26 (in Russian).
Review
For citations:
Spasov A.A., Kucheryavenko A.F., Maltsev D.V., Miroshnikov М.V., Sirotenko V.S., Sultanova К.Т., Gaidukova К.A., Skripka М.О. ACUTE TOXICITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH ANTITHROMBOGENIC PROPERTIES. Toxicological Review. 2021;1(1):52-57. (In Russ.) https://doi.org/10.36946/0869-7922-2021-1-52-57
Views:
767
Email this article 